nach oben

Erschienen in:

01.02.2018 | Pathogenesis of Hypertension (W Elliott and R Santos, Section Editors)

Angiotensin-(1–7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis

verfasst von: Fernando Pedro de Souza-Neto, Melissa Carvalho Santuchi, Mario de Morais e Silva, Maria José Campagnole-Santos, Rafaela Fernandes da Silva

Erschienen in: Current Hypertension Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review was to summarize the current knowledge on the role of angiotensin-(1–7) [Ang-(1–7)] and alamandine in experimental hypertension and atherosclerosis.

Recent Findings

The renin-angiotensin system (RAS) is a very complex system, composed of a cascade of enzymes, peptides, and receptors, known to be involved in the pathogenesis of hypertension and atherosclerosis. Ang-(1–7), identified and characterized in 1987, and alamandine, discovered 16 years after, are the newest two main effector molecules from the RAS, protecting the vascular system against hypertension and atherosclerosis.

Summary

While the beneficial effects of Ang-(1–7) have been widely studied in several experimental models of hypertension, much less studies were performed in experimental models of atherosclerosis. Alamandine has shown similar vascular effects to Ang-(1–7), namely, endothelial-dependent vasorelaxation mediated by nitric oxide and hypotensive effects in experimental hypertension. There are few studies on the effects of alamandine on atherosclerosis.

(2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the global burden of disease study 2013. Lancet 385(9963):117–71. https://doi.org/10.1016/S0140-6736(14)61682-2

Granger DN, et al. Microvascular responses to cardiovascular risk factors. Microcirculation. 2010;17(3):192–205. https://doi.org/10.1111/j.1549-8719.2009.00015.x.PubMedPubMedCentralCrossRef

Tunon J, et al. Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vasc Health Risk Manag. 2007;3(4):521–6.PubMedPubMedCentral

Bader M. ACE2, angiotensin-(1-7), and Mas: the other side of the coin. Pflugers Arch. 2013;465(1):79–85. https://doi.org/10.1007/s00424-012-1120-0.PubMedCrossRef

Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med (Berl). 2001;79(2–3):76–102. https://doi.org/10.1007/s001090100210.CrossRef

Fraga-Silva RA, Ferreira AJ, Dos Santos RA. Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension. Curr Hypertens Rep. 2013;15(1):31–8. https://doi.org/10.1007/s11906-012-0324-1.PubMedCrossRef

Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002;1(8):621–36. https://doi.org/10.1038/nrd873.PubMedCrossRef

Mazzolai L, Hayoz D. The renin-angiotensin system and atherosclerosis. Curr Hypertens Rep. 2006;8(1):47–53. https://doi.org/10.1007/s11906-006-0040-9.PubMedCrossRef

Durante A, Peretto G, Laricchia A, Ancona F, Spartera M, Mangieri A, et al. Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des. 2012;18(7):981–1004. https://doi.org/10.2174/138161212799436467.PubMedCrossRef

10.

Husain K, Hernandez W, Ansari RA, Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem. 2015;6(3):209–17. https://doi.org/10.4331/wjbc.v6.i3.209.PubMedPubMedCentralCrossRef

11.

•• Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, et al. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res. 2013;112(8):1104–1111. This paper reports the discovery and characterization of alamandine, providing first experimental data on its biological activity, biochemical profile and interaction with its receptor, MrgD. https://doi.org/10.1161/CIRCRESAHA.113.301077.PubMedCrossRef

12.

Dickson ME, Sigmund CD. Genetic basis of hypertension: revisiting angiotensinogen. Hypertension. 2006;48(1):14–20. https://doi.org/10.1161/01.HYP.0000227932.13687.60.PubMedCrossRef

13.

Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017;94:317–25. https://doi.org/10.1016/j.biopha.2017.07.091.PubMedCrossRef

14.

Bader M, Ganten D. Regulation of renin: new evidence from cultured cells and genetically modified mice. J Mol Med (Berl). 2000;78(3):130–9. https://doi.org/10.1007/s001090000089.CrossRef

15.

Gonzalez AA, Prieto MC. Roles of collecting duct renin and (pro)renin receptor in hypertension: mini review. Ther Adv Cardiovasc Dis. 2015;9(4):191–200. https://doi.org/10.1177/1753944715574817.PubMedPubMedCentralCrossRef

16.

Gonzalez AA, et al. Angiotensin II stimulates renin in inner medullary collecting duct cells via protein kinase C and independent of epithelial sodium channel and mineralocorticoid receptor activity. Hypertens. 2011;57(3):594–99.CrossRef

17.

Lavoie JL, Liu X, Bianco RA, Beltz TG, Johnson AK, Sigmund CD. Evidence supporting a functional role for intracellular renin in the brain. Hypertension. 2006;47(3):461–6. https://doi.org/10.1161/01.HYP.0000203308.52919.dc.PubMedCrossRef

18.

Nguyen G. Renin/prorenin receptors. Kidney Int. 2006;69(9):1503–6. https://doi.org/10.1038/sj.ki.5000265.PubMedCrossRef

19.

Villela DC, Passos-Silva DG, Santos RA. Alamandine: a new member of the angiotensin family. Curr Opin Nephrol Hypertens. 2014;23(2):130–4. https://doi.org/10.1097/01.mnh.0000441052.44406.92.PubMedCrossRef

20.

Bernstein KE, Gonzalez-Villalobos RA, Giani JF, Shah K, Bernstein E, Janjulia T, et al. Angiotensin-converting enzyme overexpression in myelocytes enhances the immune response. Biol Chem. 2014;395(10):1173–8. https://doi.org/10.1515/hsz-2013-0295.PubMedPubMedCentralCrossRef

21.

Crisan D, Carr J. Angiotensin I-converting enzyme: genotype and disease associations. J Mol Diagn. 2000;2(3):105–15. https://doi.org/10.1016/S1525-1578(10)60624-1.PubMedPubMedCentralCrossRef

22.

Teixeira LG, et al. Conformational properties of seven Toac-labeled angiotensin I analogues correlate with their muscle contraction activity and their ability to act as ACE substrates. PLoS One. 2015;10(8):e0136608. https://doi.org/10.1371/journal.pone.0136608.PubMedPubMedCentralCrossRef

23.

Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS One. 2011;6(12):e28501. https://doi.org/10.1371/journal.pone.0028501.PubMedPubMedCentralCrossRef

24.

Biancardi VC, Bomfim GF, Reis WL, al-Gassimi S, Nunes KP. The interplay between angiotensin II, TLR4 and hypertension. Pharmacol Res. 2017;120:88–96. https://doi.org/10.1016/j.phrs.2017.03.017.PubMedCrossRef

25.

Lacolley P, Safar ME, Regnault V, Frohlich ED. Angiotensin II, mechanotransduction, and pulsatile arterial hemodynamics in hypertension. Am J Physiol Heart Circ Physiol. 2009;297(5):H1567–75. https://doi.org/10.1152/ajpheart.00622.2009.PubMedCrossRef

26.

Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol. 2001;87(8A):25C–32C.PubMedCrossRef

27.

•• Santos RA, Brosnihan KB, Chappell MC, Pesquero J, Chernicky CL, Greene LJ, et al. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension. 1988;11(2 Pt 2):I153–I157. This paper reports for the fist time the presence of Ang-(1–7) and ECA activity in the dog brain. https://doi.org/10.1161/01.HYP.11.2_Pt_2.I153.PubMedCrossRef

28.

Schiavone MT, Santos RA, Brosnihan KB, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A. 1988;85(11):4095–8. https://doi.org/10.1073/pnas.85.11.4095.PubMedPubMedCentralCrossRef

29.

Campagnole-Santos MJ, et al. Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Phys. 1989;257(1 Pt 2):H324–9.

30.

•• Chappell MC, Brosnihan KB, Diz DI, Ferrario CM. Identification of angiotensin-(1–7) in rat brain. Evidence for differential processing of angiotensin peptides. J Biol Chem. 1989;264(28):16518–23. Using radioimmunoassays and high-performance liquid chromatography, the authors described for first time Ang-(1–7) as an endogenous product of the renin-angiotensin system, and detected in brain, adrenal and rat plasma.PubMed

31.

Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol. 2016;310(2):H137–52. https://doi.org/10.1152/ajpheart.00618.2015.PubMedCrossRef

32.

Ferrario CM, et al. Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). Adv Pharmacol. 2010;59:197–233. https://doi.org/10.1016/S1054-3589(10)59007-0.PubMedPubMedCentralCrossRef

33.

•• Santos RA, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100(14):8258–8263. By using transgenic mice and in vitro transfected cell model, the authors demonstrated for the first time the interaction between Ang-(1–7) and the Mas receptor. https://doi.org/10.1073/pnas.1432869100.PubMedPubMedCentralCrossRef

34.

Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93(5):519–27. https://doi.org/10.1113/expphysiol.2008.042002.PubMedCrossRef

35.

McCollum LT, Gallagher PE, Ann Tallant E. Angiotensin-(1–7) attenuatesangiotensin II-induced cardiac remodeling associated with upregulation of dual-specificityphosphatase 1. Am J Physiol Heart Circ Physiol. 2012;302(3):H801–H810.PubMedCrossRef

36.

Santos, RA. Angiotensin-(1–7). Hypertens. 2014;63(6):1138–47.CrossRef

37.

Jankowski V, Vanholder R, van der Giet M, Tölle M, Karadogan S, Gobom J, et al. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol. 2007;27(2):297–302. https://doi.org/10.1161/01.ATV.0000253889.09765.5f.PubMedCrossRef

38.

• Gembardt F, Grajewski S, Vahl M, Schultheiss HP, Walther T. Angiotensin metabolites can stimulate receptors of the Mas-related genes family. Mol Cell Biochem. 2008;319(1–2):115–123. This article summarizes the findings of the new components of the renin-angiotensin system with homologous sequences to Ang-(1–7) and how they interact with the Mas receptor. https://doi.org/10.1007/s11010-008-9884-4.PubMedCrossRef

39.

van Twist DJ, Kroon AA, de Leeuw PW. Angiotensin-(1-7) as a strategy in the treatment of hypertension? Curr Opin Nephrol Hypertens. 2014;23(5):480–6. https://doi.org/10.1097/MNH.0000000000000050.PubMedCrossRef

40.

Shi Y, Lo CS, Padda R, Abdo S, Chenier I, Filep JG, et al. Angiotensin-(1-7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice. Clin Sci (Lond). 2015;128(10):649–63. https://doi.org/10.1042/CS20140329.CrossRef

41.

Kangussu LM, Guimaraes PS, Nadu AP, Melo MB, Santos RAS, Campagnole-Santos MJ. Activation of angiotensin-(1-7)/Mas axis in the brain lowers blood pressure and attenuates cardiac remodeling in hypertensive transgenic (mRen2)27 rats. Neuropharmacology. 2015;97:58–66. https://doi.org/10.1016/j.neuropharm.2015.04.036.PubMedCrossRef

42.

Diez-Freire C, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006;27(1):12–9. https://doi.org/10.1152/physiolgenomics.00312.2005.PubMedCrossRef

43.

Feng Y, Xia H, Cai Y, Halabi CM, Becker LK, Santos RAS, et al. Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res. 2010;106(2):373–82. https://doi.org/10.1161/CIRCRESAHA.109.208645.PubMedCrossRef

44.

Feng Y, Yue X, Xia H, Bindom SM, Hickman PJ, Filipeanu CM, et al. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res. 2008;102(6):729–36. https://doi.org/10.1161/CIRCRESAHA.107.169110.PubMedPubMedCentralCrossRef

45.

Sriramula S, Cardinale JP, Lazartigues E, Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res. 2011;92(3):401–8. https://doi.org/10.1093/cvr/cvr242.PubMedPubMedCentralCrossRef

46.

Xia H, Sriramula S, Chhabra KH, Lazartigues E. Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. Circ Res. 2013;113(9):1087–96. https://doi.org/10.1161/CIRCRESAHA.113.301811.PubMedPubMedCentralCrossRef

47.

Xiao L, Gao L, Lazartigues E, Zucker IH. Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure. Hypertension. 2011;58(6):1057–65. https://doi.org/10.1161/HYPERTENSIONAHA.111.176636.PubMedPubMedCentralCrossRef

48.

• Guimaraes PS, Oliveira MF, Braga JF, Nadu AP, Schreihofer A, Santos RAS, et al. Increasing angiotensin-(1–7) levels in the brain attenuates metabolic syndrome-related risks in fructose-fed rats. Hypertension. 2014;63(5):1078–1085. The authors demonstrated that the chronic increase of Ang-(1–7) levels in the brain promotes cardiovascular and metabolic effects that protect animals with fructose-induced metabolic syndrome. https://doi.org/10.1161/HYPERTENSIONAHA.113.01847.PubMedCrossRef

49.

Guimaraes PS, Santiago NM, Xavier CH, Velloso EPP, Fontes MAP, Santos RAS, et al. Chronic infusion of angiotensin-(1-7) into the lateral ventricle of the brain attenuates hypertension in DOCA-salt rats. Am J Physiol Heart Circ Physiol. 2012;303(3):H393–400. https://doi.org/10.1152/ajpheart.00075.2012.PubMedCrossRef

50.

•• Santiago NM, Guimaraes PS, Sirvente RA, Oliveira LAM, Irigoyen MC, Santos RAS, et al. Lifetime overproduction of circulating Angiotensin-(1–7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension. 2010;55(4):889–896. In this work, it was demonstrated that animals with lifetime increase in circulating levels of Ang-(1–7) are protected against the damage caused by DOCA-salt hypertension model. https://doi.org/10.1161/HYPERTENSIONAHA.110.149815.PubMedCrossRef

51.

Bertagnolli M, Casali KR, de Sousa FB, Rigatto K, Becker L, Santos SHS, et al. An orally active angiotensin-(1-7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats. Peptides. 2014;51:65–73. https://doi.org/10.1016/j.peptides.2013.11.006.PubMedCrossRef

52.

Lu W, Kang J, Hu K, Tang S, Zhou X, Yu S, et al. Angiotensin-(1-7) relieved renal injury induced by chronic intermittent hypoxia in rats by reducing inflammation, oxidative stress and fibrosis. Braz J Med Biol Res. 2017;50(1):e5594. https://doi.org/10.1590/1414-431X20165594.PubMedPubMedCentralCrossRef

53.

Li P, Zhang F, Sun HJ, Zhang F, Han Y. Angiotensin-(1-7) enhances the effects of angiotensin II on the cardiac sympathetic afferent reflex and sympathetic activity in rostral ventrolateral medulla in renovascular hypertensive rats. J Am Soc Hypertens. 2015;9(11):865–77. https://doi.org/10.1016/j.jash.2015.08.005.PubMedCrossRef

54.

Du D, Chen J, Liu M, Zhu M, Jing H, Fang J, et al. The effects of angiotensin II and angiotensin-(1-7) in the rostral ventrolateral medulla of rats on stress-induced hypertension. PLoS One. 2013;8(8):e70976. https://doi.org/10.1371/journal.pone.0070976.PubMedPubMedCentralCrossRef

55.

Oscar CG, Müller-Ribeiro FCF, de Castro LG, Martins Lima A, Campagnole-Santos MJ, Santos RAS, et al. Angiotensin-(1-7) in the basolateral amygdala attenuates the cardiovascular response evoked by acute emotional stress. Brain Res. 2015;1594:183–9. https://doi.org/10.1016/j.brainres.2014.11.006.PubMedCrossRef

56.

Olivon VC, Aires RD, Santiago LB, Ramalho LZN, Cortes SF, Lemos VS. Mas receptor overexpression increased Ang-(1-7) relaxation response in renovascular hypertensive rat carotid. Peptides. 2015;71:250–8. https://doi.org/10.1016/j.peptides.2015.08.002.PubMedCrossRef

57.

•• de Almeida PW, et al. Beneficial effects of angiotensin-(1–7) against deoxycorticosterone acetate-induced diastolic dysfunction occur independently of changes in blood pressure. Hypertension. 2015;66(2):389–395. In this work the authors demonstrated that the signaling pathways involved in the cardioprotective effects of Ang-(1–7) are activated even under conditions of high blood pressure. https://doi.org/10.1161/HYPERTENSIONAHA.114.04893.PubMedCrossRef

58.

Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol. 2006;290(6):H2417–23. https://doi.org/10.1152/ajpheart.01170.2005.PubMedCrossRef

59.

Xue B, Zhang Z, Johnson RF, Guo F, Hay M, Johnson AK. Central endogenous angiotensin-(1-7) protects against aldosterone/NaCl-induced hypertension in female rats. Am J Physiol Heart Circ Physiol. 2013;305(5):H699–705. https://doi.org/10.1152/ajpheart.00193.2013.PubMedPubMedCentralCrossRef

60.

Meng W, Zhao W, Zhao T, Liu C, Chen Y, Liu H, et al. Autocrine and paracrine function of angiotensin 1-7 in tissue repair during hypertension. Am J Hypertens. 2014;27(6):775–82. https://doi.org/10.1093/ajh/hpt270.PubMedPubMedCentralCrossRef

61.

• Guo L, Yin A, Zhang Q, Zhong T, O’Rourke ST, Sun C. Angiotensin-(1–7) attenuates angiotensin II-induced cardiac hypertrophy via a Sirt3-dependent mechanism. Am J Physiol Heart Circ Physiol. 2017;312(5):H980–H991. In this paper it was demonstrated that Ang-(1–7) significantly attenuates Ang II-induced cardiac hypertrophy and perivascular fibrosis through of SOD2 expression via stimulation of Sirt3-dependent deacetylation of FoxO3a in cardiomyocytes. https://doi.org/10.1152/ajpheart.00768.2016.PubMedCrossRef

62.

Lin L, Liu X, Xu J, Weng L, Ren J, Ge J, et al. Mas receptor mediates cardioprotection of angiotensin-(1-7) against angiotensin II-induced cardiomyocyte autophagy and cardiac remodelling through inhibition of oxidative stress. J Cell Mol Med. 2016;20(1):48–57. https://doi.org/10.1111/jcmm.12687.PubMedCrossRef

63.

•• Gomes ER, et al. Angiotensin-(1–7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′,5′-cyclic monophosphate-dependent pathway. Hypertension. 2010;55(1):153–160. This paper demonstrated that the protective NO/cGMP signaling pathway is activated by Ang-(1–7) on Ang II-induced cardiomyocyte remodeling. https://doi.org/10.1161/HYPERTENSIONAHA.109.143255.PubMedCrossRef

64.

Bennion DM, Haltigan E, Regenhardt RW, Steckelings UM, Sumners C. Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke. Curr Hypertens Rep. 2015;17(2):3. https://doi.org/10.1007/s11906-014-0512-2.PubMedPubMedCentralCrossRef

65.

Jiang T, Gao L, Lu J, Zhang YD. ACE2-Ang-(1-7)-Mas axis in brain: a potential target for prevention and treatment of ischemic stroke. Curr Neuropharmacol. 2013;11(2):209–17. https://doi.org/10.2174/1570159X11311020007.PubMedPubMedCentralCrossRef

66.

• Regenhardt RW, Mecca AP, Desland F, Ritucci-Chinni PF, Ludin JA, Greenstein D, et al. Centrally administered angiotensin-(1–7) increases the survival of stroke-prone spontaneously hypertensive rats. Exp Physiol. 2014;99(2):442–453. These authors showed the beneficial effects of central administration of Ang-(1–7) on stroke-prone spontaneously hypertensive rats, a haemorrhagic stroke model, demonstrating its therapeutic potential in this disease. https://doi.org/10.1113/expphysiol.2013.075242.PubMedCrossRef

67.

Cunha TM, et al. The nonpeptide ANG-(1-7) mimic AVE 0991 attenuates cardiac remodeling and improves baroreflex sensitivity in renovascular hypertensive rats. Life Sci. 2013;92(4–5):266–75. https://doi.org/10.1016/j.lfs.2012.12.008.PubMedCrossRef

68.

Souza AP, et al. Angiotensin II type 1 receptor blockade restores angiotensin-(1-7)-induced coronary vasodilation in hypertrophic rat hearts. Clin Sci (Lond). 2013;125(9):449–59. https://doi.org/10.1042/CS20120519.CrossRef

69.

Raffai G, Durand MJ, Lombard JH. Acute and chronic angiotensin-(1-7) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats. Am J Physiol Heart Circ Physiol. 2011;301(4):H1341–52. https://doi.org/10.1152/ajpheart.00202.2011.PubMedPubMedCentralCrossRef

70.

Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension. 2010;56(1):112–20. https://doi.org/10.1161/HYPERTENSIONAHA.110.152942.PubMedCrossRef

71.

Savergnini SQ, Ianzer D, Carvalho MBL, Ferreira AJ, Silva GAB, Marques FD, et al. The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. PLoS One. 2013;8(3):e57757. https://doi.org/10.1371/journal.pone.0057757.PubMedPubMedCentralCrossRef

72.

Tetzner A, Gebolys K, Meinert C, Klein S, Uhlich A, Trebicka J, et al. G-protein-coupled receptor MrgD is a receptor for angiotensin-(1-7) involving adenylyl cyclase, cAMP, and phosphokinase A. Hypertension. 2016;68(1):185–94. https://doi.org/10.1161/HYPERTENSIONAHA.116.07572.PubMedCrossRef

73.

Soares ER, Barbosa CM, Campagnole-Santos MJ, Santos RAS, Alzamora AC. Hypotensive effect induced by microinjection of Alamandine, a derivative of angiotensin-(1-7), into caudal ventrolateral medulla of 2K1C hypertensive rats. Peptides. 2017;96:67–75. https://doi.org/10.1016/j.peptides.2017.09.005.PubMedCrossRef

74.

Soltani Hekmat A, Javanmardi K, Kouhpayeh A, Baharamali E, Farjam M. Differences in cardiovascular responses to alamandine in two-kidney, one clip hypertensive and normotensive rats. Circ J. 2017;81(3):405–12. https://doi.org/10.1253/circj.CJ-16-0958.PubMedCrossRef

75.

• Anitschkow N, Chalatow S. Ueber experimentelle Cholester-insteatose und ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse. Zentrbl Allg Pathol Pathol Anat. 1913;24:1–9. First published paper on animal model for atherosclerosis, from which further investigation emerged and, thus, helped to conceive new approaches in animal models, to improve experimental designs and to elucidate its pathophysiology.

76.

Daugherty A, Tall AR, Daemen MJAP, Falk E, Fisher EA, García-Cardeña G, et al. Recommendation on design, execution, and reporting of animal atherosclerosis studies: a scientific statement from the American Heart Association. Circ Res. 2017;121(6):e53–79. https://doi.org/10.1161/RES.0000000000000169.PubMedCrossRef

77.

Emini Veseli B, Perrotta P, de Meyer GRA, Roth L, van der Donckt C, Martinet W, et al. Animal models of atherosclerosis. Eur J Pharmacol. 2017;816:3–13. https://doi.org/10.1016/j.ejphar.2017.05.010.PubMedCrossRef

78.

Lee YT, Lin HY, Chan YWF, Li KHC, To OTL, Yan BP, et al. Mouse models of atherosclerosis: a historical perspective and recent advances. Lipids Health Dis. 2017;16(1):12. https://doi.org/10.1186/s12944-016-0402-5.PubMedPubMedCentralCrossRef

79.

Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med (Berl). 2008;86(6):615–21. https://doi.org/10.1007/s00109-008-0336-0.CrossRef

80.

Sata M, Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Investig. 2010;57(1–2):12–25. https://doi.org/10.2152/jmi.57.12.CrossRef

81.

Oliver JA, Sciacca RR. Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. J Clin Invest. 1984;74(4):1247–51. https://doi.org/10.1172/JCI111534.PubMedPubMedCentralCrossRef

82.

Swales JD, Samani NJ. Vascular RAA system. J Hum Hypertens. 1993;7(Suppl 2):S3–6.PubMed

83.

Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest. 1993;91(5):2058–64. https://doi.org/10.1172/JCI116428.PubMedPubMedCentralCrossRef

84.

Agoudemos MM, Greene AS. Localization of the renin-angiotensin system components to the skeletal muscle microcirculation. Microcirculation. 2005;12(8):627–36. https://doi.org/10.1080/10739680500301664.PubMedCrossRef

85.

Zulli A, Burrell LM, Widdop RE, Black MJ, Buxton BF, Hare DL. Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. J Histochem Cytochem. 2006;54(2):147–50. https://doi.org/10.1369/jhc.5C6782.2005.PubMedCrossRef

86.

•• Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1–7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010;30(8):1606–1613. First published paper on the role of Ang-(1–7) in experimental atherosclerosis using ApoE knockout mice model, showing that the renin-angiotensin system is able to delay the progression of atherosclerosis. https://doi.org/10.1161/ATVBAHA.110.204453.PubMedCrossRef

87.

Dong B, Zhang C, Feng JB, Zhao YX, Li SY, Yang YP, et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(7):1270–6. https://doi.org/10.1161/ATVBAHA.108.164715.PubMedCrossRef

88.

Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008;295(4):H1377–84. https://doi.org/10.1152/ajpheart.00331.2008.PubMedCrossRef

89.

Zhang YH, Zhang Yh, Dong XF, Hao QQ, Zhou XM, Yu QT, et al. ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response. Inflamm Res. 2015;64(3–4):253–60. https://doi.org/10.1007/s00011-015-0805-1.PubMedCrossRef

90.

Sluimer JC, Gasc JM, Hamming I, van Goor H, Michaud A, van den Akker LH, et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol. 2008;215(3):273–9. https://doi.org/10.1002/path.2357.PubMedCrossRef

91.

Zhang C, Zhao YX, Zhang YH, Zhu L, Deng BP, Zhou ZL, et al. Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc Natl Acad Sci U S A. 2010;107(36):15886–91. https://doi.org/10.1073/pnas.1001253107.PubMedPubMedCentralCrossRef

92.

•• Fraga-Silva RA, Savergnini SQ, Montecucco F, Nencioni A, Caffa I, Soncini D, et al. Treatment with angiotensin-(1–7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost. 2014;111(4):736–747. This paper delineates the effects of Ang-(1–7)/HPβCD orally treated ApoE knockout mice on different shear stress prone regions, adding new data about Ang-(1–7) mechanisms in atherosclerotic plaques. https://doi.org/10.1160/TH13-06-0448.PubMedCrossRef

93.

Silva AR, Aguilar EC, Alvarez-Leite JI, da Silva RF, Arantes RME, Bader M, et al. Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. Am J Phys Regul Integr Comp Phys. 2013;305(11):R1323–30. https://doi.org/10.1152/ajpregu.00249.2013.

94.

• Hammer A, Yang G, Friedrich J, Kovacs A, Lee DH, Grave K, et al. Role of the receptor Mas in macrophage-mediated inflammation in vivo. Proc Natl Acad Sci U S A. 2016;113(49):14109–14114. A new approach, by combining knockout models (Mas receptor and ApoE), allowed further investigation on the role of Mas receptor in sponteneously atherosclerotic mice, which lack ApoE expression, as well as the dynamics of these two important components in ahterosclerosis. https://doi.org/10.1073/pnas.1612668113.PubMedPubMedCentralCrossRef

95.

Yang JM, Dong M, Meng X, Zhao YX, Yang XY, Liu XL, et al. Angiotensin-(1-7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells. Arterioscler Thromb Vasc Biol. 2013;33(8):1978–85. https://doi.org/10.1161/ATVBAHA.113.301320.PubMedCrossRef

96.

Zhang F, Li S, Song J, Liu J, Cui Y, Chen H. Angiotensin-(1-7) regulates angiotensin II-induced matrix metalloproteinase-8 in vascular smooth muscle cells. Atherosclerosis. 2017;261:90–8. https://doi.org/10.1016/j.atherosclerosis.2017.02.012.PubMedCrossRef

97.

Bader M, Alenina N, Andrade-Navarro MA, Santos RA. MAS and its related G protein-coupled receptors,Mrgprs. Pharmacol Rev. 2014;66(4):1080–105. https://doi.org/10.1124/pr.113.008136.PubMedCrossRef

98.

Toton-Zuranska J, Gajda M, Pyka-Fosciak G, Kus K, Pawlowska M, Niepsuj A, et al. AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol. 2010;61(2):181–3.PubMed

99.

Jawien J, Toton-Zuranska J, Kus K, Pawlowska M, Olszanecki R, Korbut R. The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis. Med Sci Monit. 2012;18(10):Br389–93.PubMedPubMedCentralCrossRef

100.

Olszanecki R, Suski M, Gebska A, Toton-Zuranska J, Kus K, Madej J, et al. The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin I metabolism in aorta of apoE-knockout mice. J Physiol Pharmacol. 2013;64(3):317–20.PubMed

101.

Jawien J, Toton-Zuranska J, Gajda M, Niepsuj A, Gebska A, Kus K, et al. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol. 2012;63(1):77–85.PubMed

102.

• Skiba DS, et al. Anti-atherosclerotic effect of the angiotensin 1–7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis. Br J Pharmacol. 2016; Newest paper about an Ang-(1–7) analogue, AVE0991, and its role in atherosclerosis. This paper comprises previously published works on that issue and provides further information on mechanisms underlying the role of AVE0991.

103.

Habiyakare B, Alsaadon H, Mathai ML, Hayes A, Zulli A. Reduction of angiotensin A and alamandine vasoactivity in the rabbit model of atherogenesis: differential effects of alamandine and Ang(1-7). Int J Exp Pathol. 2014;95(4):290–5. https://doi.org/10.1111/iep.12087.PubMedPubMedCentralCrossRef

104.

•• Da Silva AR, Lenglet S, Carbone F, Burger F, Roth A, Liberale L, et al. Alamandine abrogates neutrophil degranulation in atherosclerotic mice. Eur J Clin Investig. 2017;47(2):117–128. First published paper on the role of alamandine in experimental atherosclerosis, extending the anti-atherosclerotic effects of the protective arm of the renin-angiotensin system to its newest characterized component. https://doi.org/10.1111/eci.12708.CrossRef

105.

• Uchiyama T, Okajima F, Mogi C, Tobo A, Tomono S, Sato K. Alamandine reduces leptin expression through the c-Src/p38 MAP kinase pathway in adipose tissue. PLoS One. 2017;12(6):e0178769. This paper brings interesting data on the effects of alamandine on plasminogen activator inhibitor-1 (PAI-1), which is a pro-atherogenic protein. However, it leaves unanswered questions whether alamandine is a pro- or an anti-atherogenic species. https://doi.org/10.1371/journal.pone.0178769.PubMedPubMedCentralCrossRef

Titel: Angiotensin-(1–7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis
verfasst von: Fernando Pedro de Souza-Neto
Melissa Carvalho Santuchi
Mario de Morais e Silva
Maria José Campagnole-Santos
Rafaela Fernandes da Silva
Publikationsdatum: 01.02.2018
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 2/2018
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-018-0798-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Angiotensin-(1–7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Integrative Physiological Aspects of Brain RAS in Hypertension

Pros and Cons of Intensive Systolic Blood Pressure Lowering

Vasopressin, Central Autonomic Control and Blood Pressure Regulation

Hypothalamic Ion Channels in Hypertension

The Global Epidemic of the Metabolic Syndrome

New Developments in Hypertensive Encephalopathy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin